Journal Watch 6/3/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Journal Watch 6/3/2024
FLOW trial: Semaglutide 1.0mg demonstrates 24% reduction in the risk of kidney disease-related events in T2DM and chronic kidney disease patients
Spatz3 Adjustable Gastric Balloon launched in the US
The number of people living with obesity passes one billion
Magnetic anchoring device assisted-LSG is safe and effective
Ultra-processed foods increase the risk of all-cause mortality and to 32 damaging health outcomes
Insulin-inhibitory receptor could be key to T2DM treatment